PCM
ALLO icon

Pentwater Capital Management’s Allogene Therapeutics ALLO Stock Holding History

Pentwater Capital Management’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-10,000
Closed -$252K – 342
2020
Q4 		$252K Hold
10,000
– – ﹤0.01% 219
2020
Q3 		$377K Hold
10,000
– – ﹤0.01% 192
2020
Q2 		$428K Buy
+10,000
New +$362K 0.01% 127

Other funds holding ALLO

TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Pentwater Capital Management's ALLO Position: Q1 2021 in Review

Pentwater Capital Management sold out of Allogene Therapeutics (ALLO) in Q1 2021, closing a stake of 10,000 shares — an estimated $252K sold.

Pentwater Capital Management first reported a position in ALLO in Q2 2020 and held it in 3 quarters. The position peaked at $428K in Q2 2020. 169 funds tracked by Wall St. Rank hold ALLO as of Q1 2021.

  • Pentwater Capital Management reported no remaining Allogene Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Pentwater Capital Management sold 10,000 Allogene Therapeutics shares in Q1 2021, an estimated $252K.
  • Pentwater Capital Management first reported a position in Allogene Therapeutics in Q2 2020 and held it in 3 quarters.
  • Pentwater Capital Management's Allogene Therapeutics position peaked at $428K in Q2 2020.
  • 169 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q1 2021.

Based on Pentwater Capital Management's 13F filing for Q1 2021, filed 17 May 2021.